PRESS RELEASE
Zeist, The Netherlands – 10 March 2026

Addressing the Manufacturing Challenge in Cell Therapy 

The promise of cell therapies is increasingly evident, yet manufacturing remains one of the industry’s most significant hurdles. As more therapies advance beyond early clinical stages, the ability to reliably expand cells at scale - without escalating costs - is becoming essential. Scalable, automated and closed manufacturing platforms are critical to enabling broader patient access and sustainable commercialization. 

Scinus has developed the Osilaris™ Platform, a closed and automated bioreactor system designed specifically to address these challenges. Osilaris enables cell cultures to expand dynamically as the cell population grows, avoiding the constraints of fixed-volume systems and supporting significantly higher expansion rates. At the same time, its proprietary oxygenation and mixing approach allows gentle, shear-free processing while maintaining tight control over critical process parameters, particularly important for sensitive cell types. 

By combining scalability with improved environmental control, the Osilaris™ bioreactor platform supports more consistent manufacturing outcomes while reducing operational complexity. The fully closed and GMP-compliant system allows integration of multiple unit operations within a single environment, lowering contamination risk, reducing manual handling steps, and decreasing GMP media consumption and labor requirements. 

The platform is commercially available and installed at leading academic ATMP manufacturers as well as multiple ATMP CDMOs in Europe, including globally recognized players. It supports a broad range of applications, including CAR-T and CAR-TCR therapies, TILs, MSCs, iPSCs, organoids, viral vector production and extracellular vesicles. 

Strategic Investor with Operational Expertise 

Dr. Wietse Mulder, Founder and Managing Partner of Myosotis Investments commented: “Advanced cell therapies require robust and scalable manufacturing solutions. Scinus has developed a differentiated platform that addresses key bottlenecks in control, scalability and cost-efficiency. I am impressed by the technological foundation of Osilaris and the team’s disciplined execution focus. We look forward to supporting Scinus in its next phase of commercial growth.” 

Dr. Dennis Schipper, Founder and CEO of Demcon, added: “Within the Demcon group, we have worked closely with Scinus to industrialize its cell expansion technology into a robust platform for cellular biotherapy manufacturing. It is rewarding to see Scinus reach this level of maturity, and we are pleased that the company is now ready to move decisively into its next phase of growth.” 

Dr. Erik Vossenaar, incoming CEO of Scinus, stated: “We are pleased to welcome Myosotis Investments as lead investor in this round and to continue the strong support from our founders and Demcon. This investment brings Scinus to the next level of organizational maturity. With a strengthened governance structure and a market-ready GMP-compliant platform, we are well positioned to execute our commercial roll-out strategy in key markets and move steadily toward profitability.”